Clinical Trial Update: A Clinical Study of TQC3721 Inhalation Powder in Patients With Chronic Obstructive Pulmonary Disease [Phase 1]

View source ↗

Summary

Ongoing Phase 1 study of TQC3721 inhalation powder for chronic obstructive pulmonary disease, with recruitment currently open.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• TQC3721 inhalation powder (TQC3721)

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Chronic Obstructive Pulmonary Disease (COPD) | Phase 1 | Status: RECRUITING